van Oortmerssen Julie A E, Mulder Janneke W C M, van der Bijl Marte F, Mijnster Ruben J M, Kavousi Maryam, Roeters van Lennep Jeanine E
Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Internal Medicine, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Curr Atheroscler Rep. 2025 Jan 28;27(1):29. doi: 10.1007/s11883-025-01275-1.
The purpose of this review is to provide an overview of the current status of lipid-lowering therapy utilization and lipid goal attainment in women. We focus on lipid-lowering therapy in individuals with and without established atherosclerotic cardiovascular disease, as well as familial hypercholesterolemia. Additionally, this review aims to explore the underlying mechanisms driving these sex differences and to identify existing knowledge gaps in this area.
Despite the proven efficacy of lipid-lowering therapy in both sexes, real-world studies indicate that women with comparable risk profiles are less likely than men to receive these treatments. Furthermore, women who are prescribed statins typically receive lower-intensity regimens than men and are less likely to achieve guideline-recommended low-density lipoprotein cholesterol goals. Despite advancements in lipid-lowering therapies, women compared to men, are systematically undertreated. This difference is influenced by patient-related, physician-related, and societal factors.
本综述旨在概述女性降脂治疗的应用现状以及血脂目标达成情况。我们重点关注有无确诊动脉粥样硬化性心血管疾病个体以及家族性高胆固醇血症患者的降脂治疗。此外，本综述旨在探讨导致这些性别差异的潜在机制，并识别该领域现有的知识空白。
尽管降脂治疗在男女两性中均已证实有效，但现实世界研究表明，具有相似风险特征的女性比男性接受这些治疗的可能性更低。此外，服用他汀类药物的女性通常比男性接受的治疗方案强度更低，且不太可能达到指南推荐的低密度脂蛋白胆固醇目标。尽管降脂治疗取得了进展，但与男性相比，女性的治疗普遍不足。这种差异受到患者相关、医生相关和社会因素的影响。
